Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 12.70% is 170% above its 5-year average of -18.25%, near the high end of its 5-year range (-285.95%–23.10%).
8.52% below its 12-month average of 13.88%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 8.91%.
EBITDA MARGIN
12.70%
EBITDA MARGIN AVG TTM
13.88%
EBITDA MARGIN AVG 3Y
-2.26%
EBITDA MARGIN AVG 5Y
-18.25%
EBITDA MARGIN AVG 10Y
-508.93%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-8.52%
CURRENT VS 3Y AVG
+662.60%
CURRENT VS 5Y AVG
+169.60%
CURRENT VS 10Y AVG
+102.50%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Xeris Biopharma Holdings, Inc.
Market Cap
$1.74B
EBITDA Margin
12.70%
TTM Avg
13.88%
3Y Avg
-2.26%
5Y Avg
-18.25%
Market Cap
$1.73B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$1.74B
EBITDA Margin
1.15%
TTM Avg
-0.80%
3Y Avg
-3.79%
5Y Avg
-4.67%
Market Cap
$1.74B
EBITDA Margin
-4034.86%
TTM Avg
-3070.57%
3Y Avg
-2386.79%
5Y Avg
-1872.66%
Market Cap
$1.71B
EBITDA Margin
-112.01%
TTM Avg
-89.88%
3Y Avg
-115.02%
5Y Avg
-95.96%
Market Cap
$1.71B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.75B
EBITDA Margin
17.09%
TTM Avg
16.59%
3Y Avg
16.89%
5Y Avg
16.75%
Market Cap
$1.70B
EBITDA Margin
-2113.29%
TTM Avg
-2694.15%
3Y Avg
-1820.79%
5Y Avg
-1820.79%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | $1.74B | 12.70% | 13.88% | -2.26% | -18.25% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -628.14% | -766.74% | -948.44% | -801.32% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 1.15% | -0.80% | -3.79% | -4.67% |
| Absci Corporation (ABSI)vs › | $1.74B | -4034.86% | -3070.57% | -2386.79% | -1872.66% |
| Novocure Ltd (NVCR)vs › | $1.74B | -20.84% | -23.57% | -26.35% | -17.29% |
| Personalis, Inc. (PSNL)vs › | $1.71B | -112.01% | -89.88% | -115.02% | -95.96% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 16.41% | 1.22% | -1.65% | 4.31% |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 17.09% | 16.59% | 16.89% | 16.75% |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.70B | -2113.29% | -2694.15% | -1820.79% | -1820.79% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | -695.72% | -791.65% | -791.65% | -791.65% |
Gross Margin
83.3%
EBITDA Margin
12.7%
Operating Margin
10.9%
Net Margin
-5.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 8.91% |
| 2026-03-31 | 13.38% |
| 2025-12-31 | 23.10% |
| 2025-09-30 | 13.34% |
| 2025-06-30 | 10.69% |
| 2025-03-31 | 0.09% |
| 2024-12-31 | 8.01% |
| 2024-09-30 | -18.00% |
| 2024-06-30 | -10.47% |
| 2024-03-31 | -27.14% |
| 2023-12-31 | -14.83% |
| 2023-09-30 | -3.22% |
| 2023-06-30 | -33.19% |
| 2023-03-31 | -30.41% |
| 2022-12-31 | -35.20% |
| 2022-09-30 | -52.85% |
| 2022-06-30 | -62.65% |
| 2022-03-31 | -117.98% |
| 2021-12-31 | -218.62% |
| 2021-09-30 | -217.81% |
| 2021-06-30 | -285.95% |
| 2021-03-31 | -200.16% |
| 2020-12-31 | -263.48% |
| 2020-09-30 | -141.42% |
| 2020-06-30 | -1079.77% |
| 2020-03-31 | -1562.30% |
| 2019-12-31 | -1739.32% |
| 2019-09-30 | -9208.36% |
| 2019-06-30 | -10573.44% |
| 2019-03-31 | -10202.82% |
| 2018-12-31 | -2514.36% |
| 2018-09-30 | -2566.67% |
| 2018-06-30 | -1499.27% |
| 2018-03-31 | -4436.12% |
| 2017-12-31 | -1960.39% |
| 2017-09-30 | -4423.53% |
| 2017-06-30 | -914.34% |
| 2017-03-31 | -1302.54% |
